NO307955B1 - Blandinger omfattende nitrogensubstituert acridin - Google Patents

Blandinger omfattende nitrogensubstituert acridin

Info

Publication number
NO307955B1
NO307955B1 NO950909A NO950909A NO307955B1 NO 307955 B1 NO307955 B1 NO 307955B1 NO 950909 A NO950909 A NO 950909A NO 950909 A NO950909 A NO 950909A NO 307955 B1 NO307955 B1 NO 307955B1
Authority
NO
Norway
Prior art keywords
mixtures
nitrogen
substituted acridine
patient
acridine
Prior art date
Application number
NO950909A
Other languages
English (en)
Other versions
NO950909L (no
NO950909D0 (no
Inventor
Thomas F Woolf
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/943,323 external-priority patent/US5422350A/en
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO950909L publication Critical patent/NO950909L/no
Publication of NO950909D0 publication Critical patent/NO950909D0/no
Publication of NO307955B1 publication Critical patent/NO307955B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Lubricants (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
NO950909A 1992-09-10 1995-03-09 Blandinger omfattende nitrogensubstituert acridin NO307955B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/943,323 US5422350A (en) 1992-09-10 1992-09-10 Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use
US08/100,917 US5466696A (en) 1992-09-10 1993-08-09 Tacrine and cytochrome P450 oxidase inhibitors and methods of use
PCT/US1993/008459 WO1994005296A2 (en) 1992-09-10 1993-09-08 Use of cytochrome p450 inhibitors for inhibiting the metabolism of nitrogen substituted acridine

Publications (3)

Publication Number Publication Date
NO950909L NO950909L (no) 1995-03-09
NO950909D0 NO950909D0 (no) 1995-03-09
NO307955B1 true NO307955B1 (no) 2000-06-26

Family

ID=26797688

Family Applications (1)

Application Number Title Priority Date Filing Date
NO950909A NO307955B1 (no) 1992-09-10 1995-03-09 Blandinger omfattende nitrogensubstituert acridin

Country Status (18)

Country Link
US (1) US5466696A (no)
EP (1) EP0659082B1 (no)
JP (1) JPH08501105A (no)
KR (1) KR950703339A (no)
AT (1) ATE212845T1 (no)
AU (1) AU669586B2 (no)
CA (1) CA2141425A1 (no)
CZ (1) CZ48095A3 (no)
DE (1) DE69331546T2 (no)
DK (1) DK0659082T3 (no)
ES (1) ES2171419T3 (no)
FI (1) FI951024A (no)
HU (1) HU217845B (no)
NO (1) NO307955B1 (no)
NZ (1) NZ256940A (no)
PT (1) PT659082E (no)
SK (1) SK26495A3 (no)
WO (1) WO1994005296A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
EP0831870A4 (en) * 1995-06-07 1998-09-16 Avmax Inc USE OF ESSENTIAL OILS TO INCREASE THE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
JP5143988B2 (ja) 1999-07-22 2013-02-13 オルガノジェネシス インク． 単離された肝細胞の機能を増強させるためのイン・ビボ誘導
AU2002367057B2 (en) * 2001-12-21 2007-01-11 Organogenesis Inc. Chamber with adjustable volume for cell culture and organ assist
AU2003270446A1 (en) * 2002-09-25 2004-04-19 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
US7583551B2 (en) 2004-03-10 2009-09-01 Micron Technology, Inc. Power management control and controlling memory refresh operations
DE102005044815A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung
WO2008153722A1 (en) * 2007-05-22 2008-12-18 The Board Of Regents Of The University Of Texas System Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2233970A (en) * 1941-03-04 Quinoline compound and process of
DE1643240A1 (de) * 1966-09-16 1971-06-24 Boehringer Sohn Ingelheim Verfahren zur Herstellung neuer racemischer oder optisch aktiver 1-Phenoxy-2-aminoalkane
GB1338169A (en) * 1971-03-09 1973-11-21 Smith Kline French Lab Ureas thioureas and guanidines
SU429813A1 (ru) * 1971-08-20 1974-05-30 Способ лечения туберкулеза легких
AR223983A1 (es) * 1978-08-25 1981-10-15 Dainippon Pharmaceutical Co Un procedimiento para-preparar derivados de acido 6-halogeno-4-oxo-7-(1-piperazinil)-1,8-naftiridin-3-carboxilico
SU789112A1 (ru) * 1979-04-12 1980-12-23 Научно-исследовательский институт экспериментальной и клинической медицины Способ лечени экстрасистолической аритмии у детей
SU827081A1 (ru) * 1979-06-05 1981-05-07 Донецкий Медицинский Институт Им.M.Горького Способ лечени вазомоторных головныхбОлЕй
GB2091249A (en) * 1980-12-23 1982-07-28 Fordonal Sa Xanthine derivatives
SU1049065A1 (ru) * 1981-01-09 1983-10-23 Andronova Liliya Z Способ лечени заикани
JPS57134482A (en) * 1981-02-13 1982-08-19 Dainippon Pharmaceut Co Ltd 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8- naphthyridine-3-carboxylic acid-3/2 hydrate and its preparation
SU1156700A1 (ru) * 1982-01-19 1985-05-23 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Способ лечени неврозов
SU1210789A1 (ru) * 1983-07-21 1986-02-15 Военно-Медицинская Ордена Ленина Краснознаменная Академия Им.С.М.Кирова Способ диагностики функционального нарушени желудочной секреции
SU1196002A1 (ru) * 1984-06-28 1985-12-07 Запорожский государственный институт усовершенствования врачей им.М.Горького Способ лечени хронического сальпингоофорита
US4695573A (en) * 1984-10-25 1987-09-22 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
US4835275A (en) * 1984-10-25 1989-05-30 Hoechst-Roussel Pharmaceuticals, Inc. Method of preparing 9-amino-1,2,3,4,-tetrahydroacridin-1-ones and related compounds
ATE63903T1 (de) * 1984-10-25 1991-06-15 Hoechst Roussel Pharma 9-amino-1,2,3,4-tetrahydroacridin-1-ol und verwandte verbindungen, verfahren zu ihrer herstellung und verwendung als arzneimittel.
US4754050A (en) * 1984-10-25 1988-06-28 Hoechst-Roussel Pharmaceuticals, Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
US4631286A (en) * 1984-10-25 1986-12-23 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
SU1537252A1 (ru) * 1985-03-28 1990-01-23 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Способ лечени парестезий полости рта
SU1416125A1 (ru) * 1986-02-21 1988-08-15 Одесский Научно-Исследовательский Институт Курортологии Способ лечени заболеваний суставов
SU1389050A1 (ru) * 1986-07-28 1990-08-30 Niiex Meditsiny An Sssr Cпocoб лeчehия aлkoгoлизma
US4816456A (en) * 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
WO1989002739A1 (en) * 1987-10-05 1989-04-06 Pfizer Inc. 4-aminopyridine derivatives
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
NZ231376A (en) * 1988-11-16 1992-05-26 Hoechst Roussel Pharma Hydroxy-1,2,3,4-tetrahydroaminoacridine derivatives, preparation and pharmaceutical compositions thereof
GB8827704D0 (en) * 1988-11-28 1988-12-29 Fujisawa Pharmaceutical Co New acridine derivatives & processes for their production
US4999430A (en) * 1989-07-31 1991-03-12 Warner-Lambert Company Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine

Also Published As

Publication number Publication date
WO1994005296A3 (en) 1994-04-28
NZ256940A (en) 1996-03-26
US5466696A (en) 1995-11-14
HU9500704D0 (en) 1995-04-28
HUT70979A (en) 1995-11-28
DE69331546D1 (de) 2002-03-21
HU217845B (hu) 2000-04-28
KR950703339A (ko) 1995-09-20
AU669586B2 (en) 1996-06-13
PT659082E (pt) 2002-07-31
ATE212845T1 (de) 2002-02-15
WO1994005296A2 (en) 1994-03-17
DK0659082T3 (da) 2002-06-17
DE69331546T2 (de) 2002-10-31
CZ48095A3 (en) 1995-12-13
AU5290593A (en) 1994-03-29
JPH08501105A (ja) 1996-02-06
NO950909L (no) 1995-03-09
CA2141425A1 (en) 1994-03-17
EP0659082B1 (en) 2002-02-06
SK26495A3 (en) 1996-05-08
NO950909D0 (no) 1995-03-09
FI951024A0 (fi) 1995-03-06
ES2171419T3 (es) 2002-09-16
FI951024A (fi) 1995-03-06
EP0659082A1 (en) 1995-06-28

Similar Documents

Publication Publication Date Title
ATE168268T1 (de) Behandlung von menschlichen retrovirus- infektionen mit 2&#39;,3&#39;-dideoxyinosin
DE68914029D1 (de) Arylmethylenderivate von Thiazolidinonen, Imidazolidinonen und Oxazolidininonen, nützlich als antiallergische Wirkstoffe und antiinflammatorische Wirkstoffe.
ATE207355T1 (de) Behandlung von hyperproliferativen gefässerkrankungen
ATE299890T1 (de) Inhibitoren von gamma-secretase
ATE233738T1 (de) Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten
NO911952L (no) Behandling av tilstander og sykdommer samt midler derfor.
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
DK0880350T3 (da) Behandling af dissemineret sklerose
FI913142A (fi) Migraenfoerhindrande alkoxipyrimidinderivat.
DE3686582D1 (de) Behandlung einer krankheit vom aids-typ.
NO307955B1 (no) Blandinger omfattende nitrogensubstituert acridin
SE9502893L (sv) Användning av kollagenas
KR970704445A (ko) 페노티아진 및/또는 티옥산틴을 사용한 알츠하이머 병의 치료 및/또는 예방 방법(methods for treating and/or preventing alzheimer&#39;s disease using phenothiazines and/or thioxanthenes
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
DE59107536D1 (de) Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose
DE68923219D1 (de) Behandlung von Abfällen.
ES2191014T3 (es) Compuestos farmaceuticos de piridina.
NO985063L (no) Pyridyl- og pyrimidyl-piperaziner i behandling av substansmisbruks forstyrr
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
EP0358432A3 (en) 1,4-dihydropyridine derivatives
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
DE68914886D1 (de) Mittel zur Behandlung von Raynaud&#39;s Krankheit.
IT1263041B (it) Derivati di s,s&#39;-bis(carbossammidofenil)-disolfuro ad attivita&#39; cardiovascolare
KR920019354A (ko) 9-아미노-1,2,3,4- 테트라하이드로아크리딘-1-올 및 관련 화합물의 aids치료용 용도